Loopholes of preferential sale approval system causes damages on pharmas

Loopholes of the preferential sale approval system, which was implemented to shorten times to commercialize generics drugs by nullifying an original product’s patent, have caused delays for generics to be launched even after getting the approval.

This is because of problems of the system which prioritized a time of getting product approval over a time of turning in approval application.

Under...